BridgeBio to Present New Analyses from Phase 3 ATTRibute-CM Trial at ESC Congress and HFSA Meeting 2024

BridgeBio Pharma, Inc., a biopharmaceutical company specializing in genetic diseases, has reported that it will present further clinical outcome data from its Phase 3 study, ATTRibute-CM, focused on acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). This data will be showcased at two major medical conferences: the European Society of Cardiology (ESC) Congress 2024, taking place in London from August 30 to September 2, and the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2024, scheduled in Atlanta from September 27 to 30.

At the ESC Congress, the presentation titled “Increase in Serum TTR Levels Observed with Acoramidis Treatment in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM): Insights From ATTRibute-CM and Its Open-Label Extension,” will be delivered by Dr. Mathew S. Maurer from Columbia University Irving Medical Center. This moderated poster session will occur on August 30 at 10:00 am ET at Station 10 - Research Gateway.

During the HFSA Annual Scientific Meeting, a detailed oral presentation entitled “Acoramidis Improves Clinical Outcomes in Patients with Transthyretin Amyloid Cardiomyopathy: A Post Hoc Recurrent Event Analysis of ATTRibute-CM,” will be provided by Dr. Daniel P. Judge from the Medical University of South Carolina, who also co-chairs the ATTRibute-CM Steering Committee. This session is scheduled for September 28 at 4:36 pm ET on the Oral Abstract Stage in the Exhibit Hall.

BridgeBio Pharma was established in 2015 with the mission of identifying, creating, testing, and delivering transformative treatments for genetic diseases. The company's development pipeline spans various stages, from initial research to advanced clinical trials. The team at BridgeBio comprises skilled professionals in drug discovery, development, and innovation, who are dedicated to leveraging advancements in genetic medicine to benefit patients swiftly. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!